Policy Influence ARM is the leading international advocacy organization with a broad network of 400+ members across 25 countries, actively shaping policies and practices in cell and gene therapies. This presents an opportunity to engage with policy and regulatory stakeholders, payer organizations, and industry partners to position our solutions as enabling tools for policy advocacy, reimbursement strategies, and market access.

Strategic Partnerships The organization collaborates with major industry bodies and research institutions (ISCT, ASGCT, academic centers) and hosts sector-wide initiatives, indicating a high potential for partnerships, sponsorships, or joint programs. Proposing co-branded studies, data analytics services, or pilot programs could align with ARM’s mission and expand reach.

Data and Analysis ARM emphasizes data-driven narratives and policy analysis, including workforce studies and sector snapshots. There is a clear need for advanced analytics, market intelligence, and benchmarking solutions to support their publications and advocacy work, creating opportunities for data services, dashboard offerings, and research support.

Market Expansion Signals Recent news highlights renewed investment activity and a recovering investor sentiment in the cell and gene therapy space, alongside ongoing policy debates. This signals readiness for tools that accelerate clinical-to-commercial translation, regulatory readiness assessments, and market access planning services across multiple geographies.

Engagement & Leadership ARM’s leadership, including the Chief Business Officer and involvement in high-profile events, suggests opportunities to offer executive-focused programs, governance advisory, and strategic consulting for member organizations seeking to navigate regulatory pathways, reimbursement, and international expansion.